Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
12.79
+0.33 (2.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
DAWN Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for DAWN stock have an average target of 36.17, with a low estimate of 24 and a high estimate of 44. The average target predicts an increase of 182.80% from the current stock price of 12.79.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 31, 2024.
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +212.74% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +158.01% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Maintains $32 → $33 | Strong Buy | Maintains | $32 → $33 | +158.01% | Oct 9, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $38 → $36 | Buy | Maintains | $38 → $36 | +181.47% | Aug 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +212.74% | Aug 1, 2024 |
Financial Forecast
Revenue This Year
123.80M
Revenue Next Year
168.49M
from 123.80M
Increased by 36.10%
EPS This Year
-0.85
from -2.37
EPS Next Year
-1.14
from -0.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 140.7M | 222.4M | 436.5M | |||
| Avg | 123.8M | 168.5M | 307.0M | |||
| Low | 56.1M | 118.1M | 232.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 79.6% | 159.0% | |||
| Avg | - | 36.1% | 82.2% | |||
| Low | - | -4.6% | 37.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.71 | -0.75 | 0.11 | |||
| Avg | -0.85 | -1.14 | -0.32 | |||
| Low | -1.52 | -1.77 | -0.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.